Abstract 2050P
Background
Anorexia is the fourth common symptom seen in half of newly diagnosed cancer patients. It also remains most prevalent and troublesome clinical problem experienced by patients with cancer during and after chemotherapy. Consequently, anorexia adversely influences nutritional status of a patient which further causes a negative impact on quality of life and survival. Various herbs have shown to be having positive effect on treating anorexia. In this study, we analysed the effect of an Ayurveda formulation consisting standardised dry powders of 5 herbs indicated in Ayurveda for treatment of Anorexia.
Methods
We did an assessment of study variables related to anorexia, cachexia and quality of life in a heterogeneous group of stage IV cancer patients (n=45) receiving conventional therapies for cancer and complaining of anorexia. These patients were administered herbal capsule “Ruchir” for treatment of Anorexia. Ruchir is consisting dry herbal powders of Pomegranate (Punica grantum), Black pepper (Piper nigrum), Ginger (Zingiber officinale), Amla (Phyllanthus emblica), Cumin (Cuminum cyminum). Therapy response on Anorexia was assessed using AC (Anorexia/cachexia subscale) and its impact on quality of life was assessed using Functional Assessment of Anorexia / Cachexia Treatment (FAACT). Weight was recorded at each visit (day 0, day 30, day 90, and day 180) using digital weighing scale. Statistical significance was assessed using nonparametric Wilcoxon Signed Ranks Test.
Results
The mean age of study participants were 64.54 (±5.6) years. Significant improvement was observed in Anorexia sub scale score (P < 0.01) and quality of life (P<0.05) as compared to baseline. No significant change was observed in weight. Treatment was well tolerated by all patients.
Conclusions
Herbs used in this study have been shown to have significant effects in reducing anorexia and improving quality of life in a heterogeneous group of cancer patients. This study provides preliminary evidence about effectiveness of herbs in treating Anorexia in cancer patients. Further controlled studies in a homogenous group of patients are warranted to integrate herbs with a standard of care in cancer patients for management of Anorexia.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
Y.N. Bendale: Other, Personal, Ownership Interest: Rasayu Cancer Clinic. All other authors have declared no conflicts of interest.
Resources from the same session
2028TiP - Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) + ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs) expressing DLL3
Presenter: Julien Mazieres
Session: Poster session 06
2029TiP - Phase I study of ABBV-706, an anti-SEZ6 antibody-drug conjugate, alone or in combination in adults with advanced solid tumors
Presenter: Sreenivasa Chandana
Session: Poster session 06
2035P - Routine biomarker monitoring does not replace comprehensive clinical assessment in the detection of immunotherapy induced myocarditis
Presenter: Alexandra Johnson
Session: Poster session 06
2036P - Prevalence and risk evaluation of cardiovascular disease among newly diagnosed prostate cancer population in China
Presenter: Weiyu Zhang
Session: Poster session 06
2037P - Prehabilitation as a strategy to improve postoperative outcomes in frail cancer patients undergoing elective surgery: A systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Poster session 06
2039P - Primary endpoints of confirmatory randomized controlled trials for older patients with cancer: A scoping review
Presenter: Tomonori Mizutani
Session: Poster session 06
2041P - The prevalence of hematologic adverse events (HAEs) and myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) in patients (pts) with advanced high grade ovarian carcinoma (aHGOC) receiving PARP inhibitor (PARPi), with or without a germline BRCA pathogenic variant
Presenter: Carmine Valenza
Session: Poster session 06
2042P - Improving breast cancer outcomes for indigenous women
Presenter: Vita Christie
Session: Poster session 06
2043P - Can Charlson Comorbidity Index (CCI) and Clinical Frailty Scale (CFS) assessments predict survival in octogenarians with colorectal cancer?
Presenter: Neda Nikolic
Session: Poster session 06
2044P - Bloodstream infections (BSI) in cancer patients: Epidemiology, antibiotic therapy and risk factors related to mortality
Presenter: Carlos López Jiménez
Session: Poster session 06